Our professionals
Dr. Rubén Hernández Alcoceba
Principal investigator of the Gene Therapy for Congenital Encephalopathies group.
Development of adenoviral vectors for gene therapy of cancer and monogenic diseases.
Professional career
Degree in Medicine, Universidad Rovira i Virgili, Tarragona 1994.
Doctor of Medicine, Universidad Autonoma Madrid, 1998.
Postdoctoral stay Cancer Center Univeristy of Michigan, Ann Arbor, MI, USA 1998-2002.
Postdoctoral stay at the Department of Internal Medicine, University of Navarra, 2003.
Researcher in the gene therapy and gene expression regulation program at CIMA since 2004.
Specialized in adenoviral vectors for gene therapy, with special interest in:
Cancer immunotherapy.
Genetic encephalopathies such as Dravet syndrome.
RESEARCH AREAS
He accumulates more than 20 years of experience in the development of gene therapy strategies for the treatment of cancer and several monogenic diseases.
Most relevant scientific achievements:
- Oncolytic adenoviruses and high-capacity adenoviral vectors for the treatment of breast, colon and pancreatic cancer.
- New tools for the production of high-capacity adenoviral vectors.
- Inducible expression systems optimized with elements of entirely human origin.
- Participation in the development of AAV vectors for the treatment of Wilson's disease.
- High-capacity adenovirus for the treatment of Dravet syndrome.
- Pioneer in gene therapy for cerebrotendinous xanthomatosis.
AREAS OF INTEREST
- Improved methods for the production of high-capacity adenoviral vectors.
- Drug-inducible gene expression systems.
- Controlled expression of immunostimulatory genes for cancer treatment.
- Gene therapy vector targeting.
- Gene therapy for Dravet syndrome.
- Gene therapy for cerebrotendinous xanthomatosis.
Activity
As an educator
- He is an associate professor of Internal Medicine and participates in the Master of Biomedical Research at the University of Navarra.
- He has been invited speaker at international gene therapy congresses.
- He has supervised 4 doctoral theses and 7 Master projects.
As a researcher
He is author of more than 60 scientific articles in international journals, 45 of them in Q1.
He has participated in more than 20 scientific projects (Spanish and European funding agencies, Government of Navarra and private foundations), being Principal Investigator in 10 of them.
He is co-author of 4 patents, one of them currently exploited by a biotechnology company.
More information
Latest scientific publications
- Engineering U1-Based Tetracycline-Inducible Riboswitches to Control Gene Expression in Mammals. Scientific Publication Dec 12, 2023 | Magazine: ACS Publications
- Viral vector-mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome Jun 15, 2023 | Magazine: Journal of Clinical Investigation